BridgeBio Pharma to Discuss Month 12 and 18 Phase 2 Cohort 5 results of Infigratinib in Achondroplasia 06.04.2024 at 8:00 AM EDT Click here for webcast Supporting Materials BBIO – Infigratinib – PROPEL 2 Data Update and ACCEL Program Initiation 872.9 KB